| P2093 | author name string | María González-Cao | |
| P2860 | cites work | EGFR inhibitors augment antitumour helper T-cell responses of HER family-specific immunotherapy. | Q39094519 |
| | Slow-cycling therapy-resistant cancer cells | Q39463009 |
| | A molecular profile of T-cell exhaustion in cancer | Q41867608 |
| | Targeting transforming growth factor beta to enhance cancer immunotherapy. | Q42747896 |
| | T cell differentiation in chronic infection and cancer: functional adaptation or exhaustion? | Q50778923 |
| | Nivolumab for squamous-cell non-small-cell lung cancer. | Q53472096 |
| | Cancer stem cell immunotherapy: the right bullet for the right target. | Q55052509 |
| | Nivolumab--an effective second-line treatment for NSCLC | Q86518313 |
| | Durable Responses With PD-1 Inhibition in Lung and Kidney Cancer and the Ongoing Search for Predictive Biomarkers | Q87200204 |
| | Improved Endpoints for Cancer Immunotherapy Trials | Q24603112 |
| | Cancer immunotherapy: a future paradigm shift in the treatment of non-small cell lung cancer | Q28082255 |
| | Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy | Q28394869 |
| | Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer | Q29615679 |
| | Pembrolizumab for the treatment of non-small-cell lung cancer | Q29620851 |
| | Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer | Q29620902 |
| | Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer | Q29620913 |
| | Surface expression patterns of negative regulatory molecules identify determinants of virus-specific CD8+ T-cell exhaustion in HIV infection | Q35001605 |
| | EGFR T790M mutation as a possible target for immunotherapy; identification of HLA-A*0201-restricted T cell epitopes derived from the EGFR T790M mutation | Q35040888 |
| | PD-1 promotes immune exhaustion by inducing antiviral T cell motility paralysis | Q36750008 |
| | PD-1/PD-L1 pathway and T-cell exhaustion in chronic hepatitis virus infection | Q37757165 |
| | The PD-1/PD-L1 (B7-H1) pathway in chronic infection-induced cytotoxic T lymphocyte exhaustion | Q37940960 |
| | The PD-1 pathway as a therapeutic target to overcome immune escape mechanisms in cancer | Q38261568 |
| | Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial | Q38364028 |
| | Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors | Q39089944 |
| P433 | issue | 6 | |
| P921 | main subject | immunotherapy | Q1427096 |
| P304 | page(s) | 675-677 | |
| P577 | publication date | 2015-12-01 | |
| P1433 | published in | Translational lung cancer research | Q26842616 |
| P1476 | title | Immunotherapy for lung cancer | |
| P478 | volume | 4 | |